araag2/HINT huggingface dataset:
Clinical trial NCT00350415 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalamine
SMILES: NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18-75 years with a confirmed diagnosis of moderately active flare of
             ulcerative colitis.

          -  Female patients need to be postmenopausal or using adequate contraception.

        Exclusion Criteria:

          -  Patients with isolated proctitis

          -  Patients with comorbidities or an investigative or commercialized treatments
             confounding interpretation of study results or compromising patients' safety in the
             trial.
Clinical trial NCT00434148 (phase 3, status: completed)
Conditions: cushing's disease
ICD codes: E24.0
Drugs: pasireotide
SMILES: NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria

          -  18 years or greater

          -  Confirmed diagnosis of ACTH-dependent Cushing's disease

          -  Not considered candidate for pituitary surgery

        Exclusion criteria

          -  History of pituitary irradiation in the last 10 years

          -  Cushing's syndrome not caused by pituitary tumor

          -  Patients with active malignant disease (cancer) in the last 5 years

          -  Women who are pregnant or lactating

        Other protocol-defined inclusion/exclusion criteria apply.
Clinical trial NCT01979679 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lurasidone 80 mg, lurasidone 120 mg, lurasidone 160 mg
SMILES: [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects are eligible to participate in this study if they:

          -  are 18 to 60 years of age at the day of first dosing.

          -  are diagnosed with schizophrenia or schizoaffective disorder.

          -  are female, subject must be using an acceptable method of birth control or be
             surgically sterile or postmenopausal. Postmenopausal is defined as no period for at
             least 12 months. Acceptable methods of birth control include oral, injectable or
             implanted contraceptives, and barrier methods such as condoms, diaphrams, and
             spermicides.

          -  are able to provide written informed consent.

          -  can safety have an MRI (no metal in the body, not claustrophobic).

        Exclusion Criteria:

        Subjects are not eligible to participate in this study if they:

          -  are treatment resisitant or intolerant to lurasidone.

          -  have had extensive radiation exposure (the study doctor will discuss this with the
             subject).

          -  if they have tremors or shaking of the limbs.

          -  are pregnant or trying to become pregnant or breastfeeding.

          -  are colorblind.

          -  have a current or past history of a major medical illness or have abnormal lab values
             which the study doctor feels is significant (any abnormal lab values will be discussed
             with the subject).

          -  are taking certain medications. The study doctor will discuss these medicines with the
             subject.

          -  have a history of alcohol, cannabis or cocaine abuse within two weeks prior to the
             study.
Clinical trial NCT01227824 (phase 3, status: completed)
Conditions: infection, human immunodeficiency virus i
ICD codes: Z21
Drugs: gsk1349572 (dolutegravir), raltegravir
SMILES: [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Screening plasma HIV-1 RNA ≥1000 c/mL

          -  Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent
             following a diagnosis of HIV-1 infection)

          -  Ability to understand and sign a written informed consent form

          -  Willingness to use approved methods of contraception to avoid pregnancy (women of
             child bearing potential only)

          -  Age equal to or greater than 18 years

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding;

          -  Active Center for Disease and Prevention Control (CDC) Category C disease

          -  Moderate to severe hepatic impairment

          -  Anticipated need for HCV therapy during the study

          -  Allergy or intolerance to the study drugs or their components or drugs of their class

          -  Malignancy within the past 5 years

          -  Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

          -  Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any
             immunomodulator within 28 days of Screening

          -  Exposure to an agent with documented activity against HIV-1 in vitro or an
             experimental vaccine or drug within 28 days of first dose of study medication

          -  Primary viral resistance in the Screening result

          -  Verified Grade 4 laboratory abnormality

          -  ALT >5 xULN

          -  ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with >35% direct bilirubin);

          -  Estimated creatinine clearance <50 mL/min

          -  Recent history (≤3 months) of upper or lower gastrointestinal bleed
Clinical trial NCT00127634 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: human insulin inhalation powder, injectable insulin, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes

          -  Non smoker

          -  Normal lung function

        Exclusion Criteria:

          -  Significant pulmonary, hepatic, or renal disease

          -  Severe congestive heart failure

          -  Active malignancy

          -  Systemic glucocorticoid therapy
Clinical trial NCT01404234 (phase 3, status: completed)
Conditions: cystic fibrosis, pseudomonas aeruginosa
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, B96.5
Drugs: azli
SMILES: C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria:

               -  Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis
                  test OR

               -  Abnormal nasal transepithelial potential difference (NPD) test OR

               -  A genotype with 2 identifiable mutations consistent with CF AND

               -  One or more clinical features consistent with CF.

          -  Documented positive lower respiratory tract culture for PA at the screening visit plus
             two documented positive lower respiratory tract cultures for PA within 12 months prior
             to study entry (must have been a minimum 3 months apart.)

          -  Clinically stable with no evidence of significant respiratory symptoms or, if obtained
             for clinical evaluation, no chest radiograph findings at screening that would have
             required administration of IV antipseudomonal antibiotics, oxygen supplementation, or
             hospitalization.

        Exclusion Criteria:

          -  Use of IV or inhaled antipseudomonal antibiotics within 14 days of study entry

          -  Presence of a condition or abnormality that would have compromised the participant's
             safety or the quality of study data, in the opinion of the investigator

          -  History of sputum or throat swab culture yielding Burkholderia spp. within 2 years
             prior to screening visit

          -  History of hypersensitivity/adverse reaction to aztreonam

          -  History of hypersensitivity/adverse reaction to beta-agonists

          -  History of lung transplantation

          -  Administration of any investigational drug or device within 30 days prior to screening
             visit or within 6 half-lives of the investigational drug (whichever was longer)

          -  Hospitalization for pulmonary-related illness within 28 days prior to screening visit

          -  Changes in or initiation of chronic azithromycin treatment within 28 days prior to
             screening visit

          -  Changes in or initiation of hypertonic saline treatment within 7 days prior to
             screening visit; for subjects on a stable regimen of hypertonic saline (28 days on/28
             days off), beginning or ending a cycle of hypertonic saline was allowed

          -  Changes in antimicrobial, bronchodilator (BD), corticosteroid or dornase alfa
             medications within 7 days prior to screening visit;

          -  Changes in physiotherapy technique or schedule within 7 days prior to screening visit

          -  Abnormal renal or hepatic function results at most recent test within the previous 90
             days
Clinical trial NCT00612742 (phase 3, status: completed)
Conditions: hypoactive sexual desire disorder
ICD codes: F52.0
Drugs: testosterone gel, placebo gel
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
Eligibility criteria:

        Inclusion Criteria:

        Postmenopausal female subjects

          -  at least 50 years of age

          -  with at least two points of cardiovascular risk

          -  with a clinical diagnosis of HSDD.

        Exclusion Criteria:

        Subjects must not

          -  require treatment with anti-androgens, high-dose oral or injectable corticosteroids,
             tamoxifen or other selective estrogen receptor modulators,

          -  have used androgen therapy within 2 months of randomization,

          -  have a history of estrogen-dependent neoplasia or any gynecologic cancer,

          -  have a history of cancer of any kind in the past 10 years prior to randomization,

          -  have a history of malignant melanoma or a history of invasive cancer at any time,

          -  have a screening mammogram with any finding that requires follow up within 6 months of
             randomization,

          -  have a history of myocardial infarction, coronary revascularization or stroke within
             12 months of randomization,

          -  have any medical condition associated with predicted survival of less than 3 years in
             the judgment of the Investigator.
Clinical trial NCT01095653 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, metformin, dapagliflozin placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 18 years old, with type 2 diabetes and with inadequate glycemic
             control

          -  Drug naive or treated with anti-diabetic medication for < 24 weeks

          -  C-peptide ≥ 1.0 ng/mL

          -  Body Mass Index ≤ 45.0 kg/m²

        Exclusion Criteria:

          -  AST and/or ALT > 3 times ULN

          -  Serum total bilirubin > 2 mg/dL

          -  Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women

          -  Creatine kinase ≥ 3 times ULN

          -  Symptoms of severely uncontrolled diabetes

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT01571453 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vortioxetine (lu aa21004), venlafaxine extended release
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™
             criteria. The current Major Depressive Episode (MDE) should be confirmed using the
             Mini International Neuropsychiatric Interview (MINI)

          -  The patient has a MADRS total score ≥26

          -  The patient has a CGI-S score ≥4

          -  The reported duration of the current MDE is ≥3 months.

        Other inclusion criteria may apply.

        Exclusion Criteria:

        - The patient meets any of the exclusion criteria listed in the protocol or, in the
        investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any
        reason.
Clinical trial NCT00159783 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have completed asenapine 3-week and 9 -week studies for the treatment of an acute
             manic or mixed episode and not had any major protocol violations..

        Exclusion Criteria:

          -  Patients with unstable medical conditions or clinically significant laboratory

        abnormalities.
Clinical trial NCT00443456 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who had completed the preceding study A0531085, Phase III study, who the
             investigator judged to be able to further treatment of long term administration in
             terms of efficacy and safety

          -  Patients who had a treatment compliance rate of at least 80%

        Exclusion Criteria:

          -  The patient who met the discontinuation criteria in the preceding study A0531085
Clinical trial NCT00435448 (phase 3, status: terminated)
Conditions: benign prostatic hyperplasia, enlarged prostate
ICD codes: N40.0, N40.1, Q84.5, R59.0, R59.1, R59.9
Drugs: lonidamine
SMILES: OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Capable of understanding the purpose and risks of the study and sign a statement of
             informed consent

          -  Male 50-80 years of age

          -  Presence of LUTS (lower urinary tract symptoms) for at least 3 months

          -  Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc

          -  Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)

          -  I-PSS (International prostate symptom score) > 12

          -  PSA > 1.0 ng/mL

          -  Must ensure and consent to use medically acceptable methods of contraception
             throughout the entire study with sexual partners of childbearing potential

          -  Able to comply with the prescribed treatment protocol and evaluations

        Exclusion Criteria:

          -  Prior treatment for BPH with alpha-blockers and/or herbal supplements in the past 2
             weeks (alpha-blockers and herbal supplements for the treatment of BPH are not allowed
             during the study). Prior treatment with 5-alpha-reductase inhibitors is allowed if
             discontinued at least 3 months prior to enrollment.

          -  Prior surgery of the prostate (except biopsies; subject is eligible to enroll one
             month after full recovery from prostate biopsy.)

          -  Current or past evidence of malignant disease of the prostate or prostatic
             intraepithelial neoplasia (for subjects with PSA between 4 - 10 ng/mL, prostate cancer
             must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA
             >10 ng/mL are excluded.)

          -  Active urinary tract infections (UTI)

          -  Active cardiac, renal or hepatic disease as evidenced by:

               1. Serum creatinine > 1.8 mg/dL

               2. ALT or AST > 2.5x the upper limit of normal at screen

               3. History of active myocardial infarction,unstable cardiac arrhythmias or stroke
                  within 6 months prior to screening

               4. Uncontrolled congestive heart failure

          -  Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)

          -  Use of systemic teriods for any reason (systemic steroid usage is not allowed during
             the study). Inhaled and/or topical steroids are allowed.

          -  Concurrent participation or participation in an investigational drug study within the
             past 30 days prior to screening

          -  Concomitant disease or condition that could interfere with the conduct of the study,
             or would in the opinion of the investigator,pose an unnaceptabele risk to the subject
Clinical trial NCT00498108 (phase 3, status: completed)
Conditions: idiopathic restless legs syndrome
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject completed the Maintenance Period and Taper Period of SP790 or SP794

        Exclusion Criteria:

          -  Subject has an ongoing serious adverse event (SAE) from SP790 or SP794 that is
             assessed to be related to the trial medication by the investigator and/or the sponsor.

          -  Subject has any medical or psychiatric condition that, in the opinion of the
             investigator, can jeopardize or would compromise the subject's ability to participate
             in this trial
Clinical trial NCT00553280 (phase 3, status: completed)
Conditions: diabetic neuropathy, painful
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who completed the 13-week treatment of painful diabetic peripheral neuropathy
             in Study A0081163.

          -  Patients must be able to understand and cooperate with study procedures and have
             signed a written informed consent prior to entering the study

        Exclusion Criteria:

          -  Patients who experienced serious adverse events in the preceding study (A0081163) that
             were determined by the investigator or the study sponsor to be causally related to the
             study medication.

          -  Patients exhibiting treatment non-compliance in the preceding study (A0081163)
Clinical trial NCT00354458 (phase 3, status: completed)
Conditions: heart failure, congestive
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: rolofylline, comparator: placebo (unspecified)
SMILES: CCCN1C2=C(NC(=N2)C23C[C@@H]4CC2C[C@H](C3)C4)C(=O)N(CCC)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. History of heart failure of at least 14 days duration for which diuretic therapy has
             been prescribed

          2. Hospitalized for acute heart failure syndrome requiring IV diuretic therapy.

          3. Impaired renal function

        Exclusion Criteria:

          1. Acute contrast induced nephropathy

          2. Ongoing or planned IV therapy for heart failure with positive inotropic agents,
             vasopressors, vasodilators, or mechanical support with the exception of IV nitrates

          3. BNP <500 pg/mL or NT-pro-BNP <2000 pg/mL

          4. Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis

          5. Severe pulmonary disease

          6. Significant stenotic valvular disease

          7. Heart transplant recipient or admitted for cardiac transplantation

          8. Clinical evidence of acute coronary syndrome in the 2 weeks prior to screening

          9. Heart failure due to significant arrhythmias

         10. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive
             cardiomyopathy.

         11. Known hepatic impairment

         12. Non-cardiac pulmonary edema, including suspected sepsis

         13. Allergy to soybean oil or eggs

         14. History of seizure

         15. Stroke within 2 years

         16. History of or current brain tumor of any etiology

         17. Brain surgery within 2 years

         18. Encephalitis/meningitis within 2 years

         19. History of penetrating head trauma

         20. Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years

         21. History of, or at risk for, alcohol withdrawal seizures

         22. Advanced Alzheimer's disease

         23. Advanced multiple sclerosis

         24. Hgb <8 g/dL, Hct <25%, or the need for a blood transfusion

         25. Previous exposure to KW-3902
Clinical trial NCT00206154 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol pmdi, budesonide pmdi, formoterol turbuhaler
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A clinical diagnosis of COPD with symptoms for more than 2 years

          -  Smoking history of 10 or more pack years

          -  A history of at least one COPD exacerbation requiring a course of oral steroids and/or
             antibiotics within 1-12 months before first visit.

        Exclusion Criteria:

          -  A history of asthma

          -  Patients taking oral steroids.

          -  Any significant disease or disorder that may jeopardize the safety of the patient